Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal (GI) diseases. The company's mission is to address significant unmet medical needs within GI health. Headquartered in Florham Park, New Jersey, United States, Phathom Pharmaceuticals was founded in 2018.

The company's core product is vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB). This innovative therapy is marketed in the U.S. under the brand name VOQUEZNA® for various indications. These include the relief of heartburn associated with Non-Erosive GERD, the healing and maintenance of healing of Erosive GERD, and as components of VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for the treatment of Helicobacter pylori (H. pylori) infection in adults.

In a notable leadership change, Steven Basta was appointed President and Chief Executive Officer and a member of the Board of Directors, effective April 1, 2025. Phathom Pharmaceuticals is actively expanding its VOQUEZNA franchise and recently completed patient enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 study of VOQUEZNA (vonoprazan) in Eosinophilic Esophagitis (EoE). The company has outlined plans to achieve profitability by 2026 and reported significant financial growth, with net revenues reaching $175.1 million in fiscal year 2025, marking a 217% increase from the prior year.